CRISPR Therapeutics

Weekly recommended science reads: stem cells, CRISPR, cancer & more

CRISPR-for-muscular-dystrophy.-Zhang-et-al.-Science-2020.-Screenshot-of-Fig.-2-featured-image

There’s never enough time to get all of one’s science reading done, but we can try! It helps to have a list of “to-read” articles, whether actual research articles or media pieces. In the old days, I remember my mentors saying they literally had “piles” of journal articles on their coffee tables, bathrooms, bedrooms, etc. …

Weekly recommended science reads: stem cells, CRISPR, cancer & more Read More »

ViaCyte Q&A: CRISPR Tx quick progress, ongoing diabetes trial, & more

ViaCyte-CyT49-PSC

ViaCyte is one of the most exciting stem cell and regenerative medicine biotech companies so I like to try to check in with them regularly. Today’s post is my new interview with ViaCyte leader Paul Laikind on recent developments. We had a great chat about the science and how things are looking upbeat for the …

ViaCyte Q&A: CRISPR Tx quick progress, ongoing diabetes trial, & more Read More »

Quick Q&A with ViaCyte CEO on CRISPR-stem cell work

VC-01-post-implant-final1-e1503703572933

We heard this week about the encouraging news of a new CRISPR-stem cell collaboration between stem cell biotech ViaCyte and CRISPR Therapeutics. The goal of the team is to make genetically engineered pancreatic derivatives from stem cells that would have a unique immune stealthiness. If such an approach was successful, patients would not need to …

Quick Q&A with ViaCyte CEO on CRISPR-stem cell work Read More »

ViaCyte & CRISPR Therapeutics team up to battle diabetes

ViaCyte

What happens when one of the most exciting stem cell biotechs ViaCyte teams up with a firm like CRISPR Therapeutics to use a combination of gene editing and cell therapy? Hopefully a synergistic partnership emerges that in this case can develop an effective stem cell-based therapy for diabetes. You can see a press release on …

ViaCyte & CRISPR Therapeutics team up to battle diabetes Read More »

The Hope of CRISPRcon: Year 2, Guest Post by Anna Everette

Anna-Everette

By Anna Everette The title of this article is partially borrowed from a fascinating Lightning Presentation delivered by John Doench of Broad Institute at CRISPRcon this year. In his talk, Mr. Doench pointed out how we’ve been looking up to this promising technology for a while now, hoping it will deliver the anticipated results (see …

The Hope of CRISPRcon: Year 2, Guest Post by Anna Everette Read More »

New #CRISPR updates: Editas to go public, patent issues, dragons & more

CRISPR-dragon

A lot has been going on in the CRISPR world. Here are some key CRISPR updates. Editas has filed the paperwork on the road to going public as a company. Such an IPO, should it come to fruition, could raise billions of dollars. Will the other CRISPR companies like Caribou and CRISPR Therapeutics follow suit? Simplistically, …

New #CRISPR updates: Editas to go public, patent issues, dragons & more Read More »